Akero Therapeutics Inc
Change company Symbol lookup
Select an option...
AKRO Akero Therapeutics Inc
PG Procter & Gamble Co
AON Aon PLC
AFRM Affirm Holdings Inc
RMI RiverNorth Opportunistic Municipal Income Fund, Inc.
NVDA NVIDIA Corp
LBAI Lakeland Bancorp Inc
BREA Brera Holdings PLC
GVYB Golden Valley Bank
DHC Diversified Healthcare Trust
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Akero Therapeutics, Inc. is a clinical-stage company that develops transformational treatments for patients with serious metabolic diseases. The Company is engaged to treat non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. The Company’s lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body. EFX is being evaluated in two Phase 2b clinical trials in patients with biopsy-confirmed NASH: a long-term follow-up period for the HARMONY study in patients with pre-cirrhotic NASH (F2-F3 fibrosis), for which it reported results after 24 weeks of treatment, and the SYMMETRY study in patients with cirrhotic NASH (F4 fibrosis, compensated). Its EFX program focused on patients with cirrhotic NASH (F4, compensated), in Phase 2b clinical trial.

Price
Delayed
$51.80
Day's Change
-1.44 (-2.71%)
Bid
--
Ask
--
B/A Size
--
Day's High
54.00
Day's Low
51.74
Volume
(Below Average)

Today's volume of 253,002 shares is on pace to be lower than AKRO's 10-day average volume of 673,357 shares.

253,002
  • Prev Close
    53.24
  • Today's Open
    53.83
  • Day's Range
    51.74-54.00
  • Avg Vol (10-day)
    673.4K
  • Last (time)
    12:19p ET 06/07/23
  • Last (size)
    100
  • 52-Wk Range
    7.52 - 54.88
    LowHigh
  • (06/13/22 - 01/03/23)
    5.61%
  • 111.3%
  • Market Cap
    2.9B
  • Shares Outstanding
    55.3M
  • -2.74
  • --
  • No dividend
  • Ex-dividend Date
    No dividend
  • Dividend Pay Date
    No dividend
  • -0.9
  • 85.66
  • (% of float 05/15/23)
    9.08

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.